We have evaluated and compared the efficacy of systemic administration of lipoplex formulations containing plasmids encoding IFN-b or IFN-g, and a synthetic double-strand RNA poly I:poly C (pI:pC), a type I IFN inducer, in a lung metastasis model in which colon carcinoma CT-26 cells were inoculated intravenously into immunocompatible mice. Injection of lipoplexes containing plasmid DNA, regardless of IFN gene insertion, stimulated a transient increase in the serum concentration of proinflammatory cytokines such as tumor necrosis factor (TNF)-a and IFN-g, while injection of lipoplexes containing pI:pC led to a low level of TNF-a and undetectable IFN-g production. Furthermore, injection of these lipoplexes containing plasmids resulted in the production of a mixture of type I and type II IFNs, partly derived from the inserted IFN genes, in lung tissue cultures. In tumor-prophylactic experiments, intravenous injection of lipoplexes containing plasmid, regardless of IFN gene insertion, showed a significant reduction in lung metastatic nodules probably due to proinflammatory cytokines such as TNF-a and IFN-g nonspecifically induced by the CpG motifs in the plasmid and the type I IFNs produced. On the other hand, the antimetastatic effect of pI:pC-lipoplex seemed to be due mainly to IFN-b induced by pI:pC. In established lung metastasis experiments, a single intravenous administration of lipoplexes containing IFN-b gene or pI:pC, but not other lipoplexes, showed a significant therapeutic effect on the tumor metastasis: reduction in tumor nodules and prolongation of survival time of tumor-burden mice. The therapeutic effects were specifically impaired by anti-IFN-b antibody treatment, indicating that IFN-b produced by the lipoplexes played an important role in the suppression of established metastatic lung tumors. Thus, the local IFN-b in the lung delivered by intravenous administration of lipoplex containing IFN-b gene or pI:pC may be a convenient and useful method of inhibiting established metastatic lung tumors.
C ytokine-supported tumor immunotherapy or tumor vaccination is one of the most promising strategies for cancer gene therapy. Among the many cytokine genes, interferon (IFN) genes are considered to be useful for this purpose, since IFNs have diverse biological functions, including antiproliferative and immunomodulatory activities, which are capable of contributing to the host's defense against tumors. [1] [2] [3] In fact, IFN genes are being used in both clinical and preclinical trials of ex vivo as well as in vivo cancer gene therapy. [4] [5] [6] [7] ; the type I IFN (IFN-a or -b) [8] [9] [10] [11] [12] [13] and type II IFN (IFN-g) genes 6, 7, 14, 15 are administered locally (e.g. intratumoral or intraperitoneal injection) via viral and nonviral vectors. Systemic IFN gene delivery may be useful for the treatment of disseminated or metastatic tumors. 13 A nonviral plasmid-based vector complexed with liposome, lipoplex, has advantages for systemic administration; it features simplicity of preparation, low toxicity and low immunogenicity, so that it is attractive as an efficient vector for in vivo IFN gene delivery.
Previous studies have demonstrated that intravenous injections of lipoplexes result in efficient gene expression in the lungs. [16] [17] [18] Depending on the lipoplex formulation used, the level of gene expression in the lungs was 10-10,000-fold higher than those in other organs. Thus, the simple gene delivery strategy can be an effective approach for the treatment of lung diseases including pulmonary metastasis of tumor cells. Actually, we and other groups have demonstrated that the lung endothelial cells are largely responsible for the efficient gene expression in the lung following lipoplex administration. 18, 19 It has been shown that lung metastases are initiated on attachment of tumor cells to the vascular endothelium and pulmonary tumor nodules arise from attached intravascular tumor cells. 20 In addition, the growth of tumors appears to depend on angiogenesis, and angiogenic endothelial cells can take up lipoplexes more efficiently. 21 In the present study, we evaluated the potential of lipoplexes containing plasmid DNA encoding mouse IFN-b and IFN-g genes in a lung metastasis model using mouse colon tumor CT-26 cells. The cationic liposomes used were composed of N-(1-2,3-dioleyloxypropyl)-N,N,N-trimethylammonium (DOTMA) and cholesterol (Chol) as a neutral helper lipid because this formulation displayed a high in vivo transgene expression in the lung following intravenous administration without any serious side effects. 19, 22, 23 We also used the lipoplex formulation of a synthetic double-strand RNA pI:pC, a potent type I IFN inducer, for comparison.
Materials and methods

Chemicals
DOTMA was purchased from Tokyo Kasei (Tokyo, Japan) and Chol was obtained from Nacalai Tesque Inc. (Kyoto, Japan). RPMI 1640 medium and Eagle's minimum essential medium (MEM) were purchased from Nissui Pharmaceutical (Tokyo, Japan). pI:pC was purchased from Pharmacia Biotech (Uppsala, Sweden). Rat IgG was obtained from CHEMICON International, Inc. (Temecula, CA).
Plasmid DNA pcDNA3 was purchased from Invitrogen (Carlsbad, CA). pCMV-Mug and pCMV-Mub were constructed using pcDNA3 as described previously. 14, 24 Plasmid DNA was amplified in Escherichia coli strain DH5a and then isolated and purified using a QIAGEN plasmid Giga Kit with an EndoFree plasmid maxi kit (Qiagen GmbH, Hilden, Germany). The lipopolysaccharide (LPS) concentration in the plasmid DNA preparation, which was measured using an LAL assay kit (Limus F Single Test Wako, Wako; Pure Chemical, Osaka, Japan) according to the manufacturer's instructions, was less than 22 pg/mg DNA. The purity and integrity of the plasmid DNA were determined by absorbance at 260 and 280 nm and gel electrophoresis on 1% agarose.
Preparation of cationic liposomes and lipoplexes
Cationic liposomes (DOTMA:Chol, 1:1 molar ratio) were prepared by allowing the lipids to dry as a thin film in a round-bottomed flask using a rotary evaporator, followed by resuspending the dried film in 5% (w/v) dextrose solution by vortexing and subsequent sonication for 5 minutes in a bath sonicator. Plasmid DNA or pI:pC solutions (each 2 mg/ml) were added to the DOTMA/ Chol liposome suspension (1 mg/ml DOTMA) at a charge ratio of +2.24 and the complexed mixtures, called lipoplexes, were incubated at room temperature for 30 minutes before use.
Cell cultures and mice
Mouse colon tumor CT-26 cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 10 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin and maintained in a 5% CO 2 incubator at 371C. L cells were cultured in 2 mg/ml glucose-containing MEM supplemented with 6% FCS. Five-week-old male CDF 1 mice, obtained from Shizuoka Agricultural Cooperative Association for Laboratory Animals (Shizuoka, Japan), were used for animal experiments.
Secretion of IFNs from the lung tissues after intravenous injection of lipoplexes into mice
The amounts of IFNs secreted from the lung tissues isolated from the mice that had received intravenous lipoplexes were determined as follows. At 2 hours after intravenous injection of the lipoplexes, DOTMA/Chol liposomes containing 25 mg pcDNA3 (noncoding-lipoplex), pCMV-Mub (Mub-lipoplex), pCMV-Mug (Muglipoplex), or 12.5 mg pI:pC (pI:pC-lipoplex), or 5% (w/v) dextrose solution per mouse were injected into the tail vain, the lungs were perfused with saline to remove the blood completely and then the whole lungs were removed. The lung tissues were washed and minced with a scalpel, and then cultured in a 24-well dish with 1 ml medium (10% FCS-RPMI1640) for 4 hours in a CO 2 incubator at 371C. The supernatants were harvested, passed through a 0.45 mm filter and subjected to IFN bioassay (see below).
IFN bioassay
The IFN activity of the supernatants was measured by the reduction in the cytopathic effect of vesicular stomatitis virus on L cells as described elsewhere. 25 Subtypes of IFNs were determined by combinational uses of neutralizing monoclonal rat antibodies against mouse IFN-a (4E-A1), 26 IFN-b (7F-D3), 26 and IFN-g (R4-6A2) 27 in a bioassay.
Determination of proinflammatory cytokines in serum after intravenous injection of lipoplexes
Blood was collected from mice by retro-orbital bleeding 3 hours (for TNF-a) and 6 hours (for IFN-g) after intravenous injection of lipoplexes, or pcDNA3 or DOTMA/Chol liposome alone into the mice. The blood was allowed to coagulate for 2-3 hours at 41C and serum was isolated as the supernatant fraction following centrifugation at 5000 rpm for 5 minutes. The serum samples were immediately stored at À801C until the enzyme-linked immuno-sorbent assay (ELISA). The amounts of TNF-a and IFN-g in the sera were analyzed using ELISA kits (Genzyme, Cambridge, MA) according to the manufacturer's protocols.
Intravenous administration of lipoplexes in a lung metastasis model
We evaluated the prophylactic and therapeutic effects of an intravenous injection of various lipoplexes on lung metastases of CT-26 cells. For inoculation into mice, the cells were trypsinized to prepare single-cell suspensions in Hank's balanced salt solution (HBSS); the number of viable cells was counted with a hemocytometer. Fiveweek-old immunocompatible male CDF 1 mice were intravenously injected with 100 ml CT-26 cell suspension (1 Â 10 6 cells/ml HBSS) via the tail vein. In prophylactic experiments, 6 hours prior to the tumor cell inoculation, mice were injected intravenously with 200 ml lipoplexes containing 25 mg each plasmid DNA or 12.5 mg pI:pC per mouse via the tail vein. As a control, a group of mice received 5% dextrose solution in a similar manner. The mice were killed 17 days after the injection to examine the tumor burden in the lung; the number of pulmonary metastatic nodules per lung was counted.
In therapeutic experiments for established lung metastastic tumors, 7 days after tumor cell inoculation, the tumor-bearing mice were given a single intravenous injection of 200 ml lipoplexes containing 25 mg of each plasmid DNA or 12.5 mg pI:pC per mouse, or 5% dextrose solution via the tail vein. The mice were killed 10 days after the lipoplex treatment, and the number of pulmonary metastatic nodules per lung was counted to evaluate the therapeutic effect. The survival time of mice with lung metastasis was also measured.
Treatment of anti-IFN antibodies in therapy experiments in established lung metastasis
In order to examine the IFN types involved in the therapeutic effects of lipoplexes in established lung metastasis models, neutralization experiments were carried out using various anti-IFN antibodies. At 12 hours before intravenous injection of lipoplexes containing pCMV-Mub or pI:pC, 200 mg anti-IFN-b antibody (7F-D3), anti-IFN-g antibody (R4-6A2), or normal rat IgG in 100 ml HBSS, or 100 ml saline (HBSS) alone was intraperitoneally injected into the tumor-bearing mice. The mice were killed 10 days after lipoplex injection and the number of metastatic nodules in the lung was counted.
Statistical analysis
Data on metastatic tumor nodules in the lung were expressed as means 7 SD and analyzed by ANOVA. The survival time of mice was assessed on a KaplanMeier survival plot followed by a Logrank (Mantel-Cox) test.
Results
IFN production from mouse lung after intravenous administration of lipoplexes
We examined the amounts of IFNs produced from the lung tissues in culture isolated from CDF 1 mice that had received intravenous lipoplexes containing plasmid DNA or pI:pC. Unexpectedly, any lipoplex containing plasmid DNA, independent of the encoding gene insertion, showed production of substantial amounts of IFN activity from the lungs (Fig 1) . Also, the IFN activity was composed of various IFN subtypes and roughly equal to their summation. Interestingly, IFN-a activity was released in lipoplexes containing plasmid DNA much more than in lipoplex containing pI:pC (pI:pC-lipoplex). Thus the nonspecific IFN-a induction observed is probably due to the CpG motifs in plasmids. In contrast, such nonspecific IFN-b or IFN-g production in lipoplex containing plasmid DNA was poor, and the relatively higher production of IFN-b or IFN-g corresponded to the lipoplex containing pCMV-Mub (Mub-lipoplex) or pCMV-Mug (Mug-lipoplex), respectively, suggesting that the inserted IFN gene-specific expression also took place in the lung after lipoplex administration. The lung tissues from mice injected with the pI:pC-lipoplex released mainly IFN-b with a small amount of IFN-a and negligible IFN-g.
Nonspecific induction of TNF-a and IFN-g after intravenous administration of the lipoplexes
The nonspecific CpG motif-mediated induction of proinflammatory cytokines (e.g., TNF-a, IFN-g, IL-12) had been observed previously by us and other investigators after either intravenous or direct intratumoral administration of lipoplexes. 14, 22, 28, 29 To confirm such cytokine induction by the lipoplexes used in this study, the levels of TNF-a and IFN-g in the serum were measured and found IFN gene delivery to lung metastasis F Sakurai et al to increase transiently with a peak at 3 and 6 hours after injection, respectively (data not shown). Intravenous administration of noncoding-, Mub-, and Mug-lipoplexes produced about 800 pg/ml TNF-a and 50,000 pg/ml IFNg in the serum, whereas injection of plasmid DNA or DOTMA/Chol liposome alone induced only a small amount of these cytokines (Fig 2) . There were no significant differences between the cytokine levels induced by the three types of lipoplexes, suggesting that the cytokine induction was due to the common plasmid DNA rather than the inserted IFN genes, presumably to the CpG motifs in the parental plasmid. pI:pC-lipoplex administration also induced a substantial amount of TNF-a and an undetectable amount of IFN-g.
Prophylactic effect of intravenous injection of lipoplexes on lung metastases
We examined the prophylactic effect of injection of lipoplexes on lung metastases. The lipoplexes were intravenously injected into mice 6 hours before CT-26 cell inoculation. All types of lipoplexes potently inhibited the lung metastases of CT-26 cells (Fig 3) , suggesting that both proinflammatory cytokines and type I IFNs induced by the lipoplex-containing plasmid as well as by pI:pClipoplex would affect the lung metastatic processes of CT-26 cells.
Therapeutic effect of intravenous delivery of lipoplexes on established lung metastatic tumors
Next, we evaluated the antitumor effects of the lipoplexes on established lung metastatic tumors. Each type of lipoplex was given as a single intravenous injection 7 days after tumor cell inoculation followed by estimation of the tumor nodules formed in the lung and the survival time of the tumor-bearing mice as compared with 5% dextrose treatment. Injection of Mub-lipoplex or pI:pC-lipoplex exhibited efficient suppressive effects, as quantified by the number of lung tumor nodules, while noncoding-lipoplex or Mug-lipoplex did not show any significant therapeutic effect (Fig 4) . Consistently, the survival times of the mice treated with Mub-lipoplex or pI:pC-lipoplex were prolonged than those of the mice treated with other types of lipoplexes (Fig 5) .
Neutralization of antitumor effects of the lipoplexes by anti-IFN antibody administration
In order to clarify the role of IFN-b in the antimetastatic effects of Mub-lipoplex and pI:pC-lipoplex injections, anti-IFN antibodies were administered intraperitoneally 12 hours before lipoplex injection. As controls, normal rat IgG or saline was administered. As shown in Figure 6 , pretreatment with anti-IFN-b antibody completely abrogated the antitumor effects of Mub-lipoplex and pI:pClipoplex, whereas normal rat IgG or anti-IFN-g antibody Figure 2 Serum levels of proinflammatory cytokines. Mice were intravenously injected with various lipoplexes as in Figure 1 , or pcDNA3 or DOTMA/Chol liposome alone. At 3 and 6 hours after injection, serum was collected and assessed, respectively, for TNF-a (a) and IFN-g (b) levels by ELISA. Each value represents the mean7SD of three mice. cells per mouse. At 7 days after cell inoculation, mice were treated with a single intravenous injection of the lipoplexes. The mice were killed 17 days after cell inoculation, and the number of pulmonary metastatic nodules per lung was determined. Each result represents the mean7SD of nine to ten mice. Statistically significant difference; **Po.01, versus non-coding-lipoplex.
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had no significant effect compared with saline. These data suggest that IFN-b induced by the lipoplex injection is predominantly responsible for the antitumor effects of these lipoplexes on established lung metastases.
Discussion
It is well known that efficient and selective transgene expression can be seen in the lung following intravenous injection of lipoplexes. [16] [17] [18] Besides the gene expression in the lung, such lipoplex administration can provoke a systemic Th1-like innate immune response, which is accompanied by the production of proinflammatory cytokines such as TNF-a, IFN-g and IL-12. 22, 28, 30 It has been shown that bacterial DNA, plasmid DNA, and oligonucleotides, having the unmethylated CpG motifs, are recognized as a danger signal and activate cells which are competent in the innate immune system, such as macrophages and dendritic cells, to secrete proinflammatory cytokines in a nonspecific manner. [31] [32] [33] Our recent study has revealed that tissue macrophages, in particular, liver Kupffer cells and spleen macrophages, play an important role in the in vivo induction of these cytokines, probably mediated by the CpG motifs of lipoplexes injected into mice. 22 Thus, the lipoplex-mediated nonspecific proinflammatory cytokine induction or innate immune activation could be advantageous for cancer therapy partly because of the cytotoxic and immunomodulatory effects of the cytokines, although these cytokines may occasionally inhibit transgene expression. 22, 34, 35 Based on these findings, several studies were carried out to assess the potential of lipoplexes as systemic delivery vehicles for therapeutic genes, such as p53 and IL-12, 28, 29, 36 for the treatment of malignant tumors. In many cases, the antitumor activities observed were ascribed to the nonspecific induction of cytokines rather than expression of the therapeutic transgenes.
In the present study, we evaluated the efficacy of systemic administration of lipoplexes containing IFN-b and IFN-g genes (Mub-lipoplex and Mug-lipoplex, respectively) and pI:pC (pI:pC-lipoplex) in a lung metastasis model using CT-26 cells. Intravenous administration of these lipoplexes caused efficient expression of the transferred IFN genes in the lung compared with those in other organs (not shown), in accordance with previous reports. [16] [17] [18] In addition, unexpectedly, lipoplex administration stimulated marked production of IFN-a and only weak production of IFN-g, although the mechanism is still unknown. Meanwhile, pI:pC-lipoplex, lacking the CpG motifs, induced the expression of IFN-b (or IFN-b and -a) without any marked induction of other cytokines.
Mice were administered with 25 mg plasmid DNA complexed with the cationic liposome, whereas we injected the lipoplex containing 12.5 mg pI:pC into mice. We found that 80% of the mice died the next day after intravenous administration of lipoplex containing 25 mg pI:pC (data not shown). We also confirmed that the in vivo transfection efficiency of lipoplexes in the lung at the dose of 12.5 mg plasmid DNA was 5-20-fold lower than that at the dose of 25 mg plasmid DNA (data not shown), suggesting that the therapeutic effects of the lipoplexes would be largely reduced at the dose of 12.5 mg plasmid DNA. Therefore, we performed the therapeutic experiments at these doses.
In prophylactic experiments, intravenous injection of all types of lipoplexes, including noncoding-lipoplex containing noncoding plasmid and pI:pC-lipoplex, showed a similar substantial reduction in lung metastatic nodules (Fig 3) . For this nonspecific therapeutic effect, an early treatment (at the latest 4 days after cell inoculation) seemed to be important (data not shown). These results are in agreement with previous findings in different tumor models. 29 Dow et al reported that intravenous adminis- IFN gene delivery to lung metastasis F Sakurai et al tration of lipoplex containing noncoding plasmid DNA can significantly inhibit the growth of early metastatic lung tumors (3 days after inoculation), although it did not inhibit the growth of late metastatic lung tumors (6 days after inoculation). A marked nonspecific induction of cytokines such as TNF-a and IFN-g is seen in blood (Fig 2) , and IFN-b induction in pI:pC-lipoplex may be responsible for the prophylactic suppression of tumor metastasis, although the underlying mechanisms are unclear.
In the established lung metastatic experiments, Mublipoplex and pI:pC-lipoplex, but not Mug-lipoplex or noncoding-lipoplex, produced a marked reduction in the metastatic nodules in the lung (Fig 4) and significant prolongation of the survival time of tumor-burden mice (Fig 5) . In the neutralization experiments with specific IFN antibodies (Fig 6) , anti-IFN-b antibody impaired completely the therapeutic potential of both lipoplexes, but anti-IFN-g antibody did not affect the antitumor effect, suggesting that IFN-b produced in the lung by these lipoplexes plays a crucial role in the inhibition of established lung metastatic tumors of CT-26 cells. Although there were no significant differences between the numbers of metastatic nodules in the lungs of the mice given lipoplexes containing IFN-g gene and noncoding plasmid (Fig 4) , the survival of tumor-bearing mice was significantly prolonged by treatment with these lipoplexes compared with the controls (see Fig 5) . In addition, the survival times of the tumor-bearing mice treated with Mub-lipoplex and pI:pC-lipoplex were significantly longer compared with noncoding-lipoplex, however, not dramatically prolonged in spite of the efficient suppressive effect of these formulations on the tumor nodules. These results imply that the cytokine production nonspecifically induced by lipoplexes might improve this survival parameter slightly, although its therapeutic effect was much lower than that of IFN-b produced by Mublipoplex and pI:pC-lipoplex.
CpG motif in the plasmid DNA would play an important role in the lipoplex-mediated induction of the inflammatory cytokines. Yew et al reported that they constructed a CpG-depleted plasmid DNA and that intravenous administration of lipoplex containing the CpG-depleted plasmid DNA resulted in decreased levels of IL-12 and IFN-g inductions compared with the unmodified plasmid DNA, although there were no longer measurable differences between the unmodified and CpGdepleted plasmid DNA with regard to the number of leukocytes and platelets. 37 On the other hand, it is possible that unknown toxic components in plasmid DNA might be involved in the production of the inflammatory cytokines. Yasuda et al showed that lipoplexes activated murine macrophages to induce the cytokines in a CpG motif-independent manner. 38 McLachlan et al demonstrated that lipoplexes containing methylated plasmid DNA, as well as lipoplexes containing unmethylated plasmid DNA, caused severe inflammation in the lung, suggesting that other factors involved in the inflammation are unaffected by methylation of plasmid DNA. 39 Other methylated motifs different from the conventional CpG motif (5 0 -Pur-Pur-CG-Pyr-Pyr-3 0 ) may also contribute to lipoplex-mediated inflammatory response. 40 Local production of IFN-b in the lung appears to be important for the antitumor effect on established lung metastases. Dong et al 41 have also suggested that the tumor growth inhibitory effect of IFN-b was local and not systemic based on the finding that IFN-b-transduced cells did not inhibit the growth of parental cells administered subcutaneously at a distant site. It is well known that IFN-b has many biological effects. 42, 43 IFN-b exhibits antitumor effects via various mechanisms, such as upregulation of MHC class I, 44 activation of macrophages and NK cells, 45 downregulation of angiogenic agents 46 and inhibition of tumor cell proliferation. 47 It is likely that inhibition of tumor cell proliferation by IFN-b is one of the most important mechanisms in our study, because the cell growth inhibitory effect of IFN-b was often higher than that of IFN-a and g 47, 48 and, in fact, the in vitro growth of CT-26 cells was efficiently inhibited by IFN-b. 49 The lung metastasis of the CT-26 cells examined in this work may be much more sensitive to IFN-b than IFN-a. It has been reported that NK cells play an important role in the antitumor effect after intravenous administration of lipoplexes. 30 Intravenous administration of noncoding-lipoplex induced NK cell activation and accumulation in the lung 30 and IFN-b also activated NK cells. 45 In addition, NK cells recognize effectively tumor cells which do not express MHC class I. 50 As CT-26 cells express MHC class I, 51 it is unlikely that NK cells are involved significantly in the suppression of established lung metastasis of CT-26 cells in our study.
The selection of promoter which drives transgene in plasmid DNA is very critical for transfection efficiency. In this study, we selected cytomegalovirus (CMV) promoter for the expression of IFN-b and -g, which is commonly used in transfection experiments. Recently, various types of promoters have been constructed, which shows higher levels of gene expression than CMV promoter. 52, 53 In addition to the promoter, other transcriptional regulatory elements, such as intron and polyadenylation signal sequence, are also important. 54 The use of optimized transgene expression cassette would make lipoplexmediated gene therapy more efficient.
In conclusion, the present study has provided useful information on the efficacy of lipoplex treatment of metastatic tumors. Initial or relatively early events in tumor metastasis are suppressed by this method, probably related to nonspecifically produced proinflammatory cytokines and/or IFN-b induced by pI:pC. On the other hand, later stage tumor metastasis or development of metastasized lung tumors was predominantly inhibited by IFN-b, probably expressed locally in the lung. Thus, pulmonary-targeted IFN-b delivery by intravenous administration of lipoplexes containing the IFN-b gene may be a convenient and useful method of inhibiting the growth of established lung metastases. The pI:pC-lipoplex will also be a promising and useful agent for tumor metastasis, and it will enable us to examine the in vivo effects of IFN-b (or IFN-b and -a) without any remarkable induction of other cytokines.
